Latde Diagnostics

Impact

Latde is developing a platform that produces a rapid, amplifiable readout for antibiotic susceptibility.

Current rapid antibiotic testing solutions are expensive, require expensive equipment, and therefore out of reach for most hospitals in the world.

Latde aims to reduce the duration and cost of pathogen detection and antibiotic susceptibility profiling, in turn saving lives, shortening hospital stays, containing hospital costs, and promoting antibiotic stewardship.

Contact Info

Sloan Siegrist, PhD
Co-Founder

Emily Melzer, PhD
CEO and Co-Founder

Carolina Santamaria
PhD Student

Contact Us

siegrist@microbio.umass.edu 
​​​​​​latdedx.com